These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 118835)

  • 1. Cellular immunity in patients with meningococcal disease and in vaccinated subjects.
    Greenwood BM; Oduloju AJ; Ade-Serrano MA
    Clin Exp Immunol; 1979 Oct; 38(1):9-15. PubMed ID: 118835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal vaccines.
    Bethell D; Pollard AJ
    Expert Rev Vaccines; 2002 Jun; 1(1):75-84. PubMed ID: 12908514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of meningococcal meningitis with meningococcal vaccines.
    Artenstein MS
    Yale J Biol Med; 1975 Jul; 48(3):197-200. PubMed ID: 808913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Right age for Meningococcal vaccine.
    John TJ
    Indian Pediatr; 1998 Jul; 35(7):669-70. PubMed ID: 10216680
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immune response to meningococci].
    Flaegstad T
    Tidsskr Nor Laegeforen; 1989 Jan; 109(1):33-6. PubMed ID: 2492123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine.
    Rosenqvist E; Tjade T; Frøholm LO; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):139-49. PubMed ID: 6427704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 8. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease.
    Litt DJ; Savino S; Beddek A; Comanducci M; Sandiford C; Stevens J; Levin M; Ison C; Pizza M; Rappuoli R; Kroll JS
    J Infect Dis; 2004 Oct; 190(8):1488-97. PubMed ID: 15378443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of meningococcal polysaccharide vaccine serogroup "A" (Pilot Study).
    Bahl MR
    Med J Zambia; 1975 Dec-1976 Jan; 9(6):166. PubMed ID: 818845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy.
    McCormick JB; Gusmão HH; Nakamura S; Freire JB; Veras J; Gorman G; Feeley JC; Wingo P
    J Clin Invest; 1980 May; 65(5):1141-4. PubMed ID: 6767739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies].
    Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV
    Sante; 1997; 7(6):384-90. PubMed ID: 9503496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic].
    Wu C
    Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Dec; 6(6):344-6. PubMed ID: 3938683
    [No Abstract]   [Full Text] [Related]  

  • 13. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37.
    Krizova P; Musilek M
    Cent Eur J Public Health; 1995 Nov; 3(4):189-94. PubMed ID: 8903519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tetravalent anti-meningococcal vaccine: serologic and clinical evaluation].
    Vescia N; Mastroeni I; Pompa MG; Signorelli C; Fara GM
    Ann Ig; 1989; 1(6):1293-8. PubMed ID: 2484465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defences against meningococcal infections.
    Lancet; 1985 Oct; 2(8461):929-30. PubMed ID: 2865427
    [No Abstract]   [Full Text] [Related]  

  • 16. [Serological evaluation of polyvalent A-C anti-meningococcal vaccine in Chile].
    García Moreno J; Prat Miranda MS; Vicent P; Calderón B
    Bol Oficina Sanit Panam; 1982 Aug; 93(2):149-57. PubMed ID: 6215047
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of complement in anti-bacterial defence.
    D'Amelio R; Biselli R
    Ann Ital Med Int; 1994; 9(3):173-7. PubMed ID: 7946895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [efficacy of the polysaccharide vaccine of Neisseria meningitidis group A].
    Yuan CD
    Zhonghua Liu Xing Bing Xue Za Zhi; 1983 Aug; 4(4):207-10. PubMed ID: 6416682
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of the effectiveness of targeted vaccination with the meningococcal polysaccharide A and C vaccine in one location in the Czech Republic].
    Krízová P; Vlcková J; Bobák M
    Epidemiol Mikrobiol Imunol; 1995 Mar; 44(1):9-14. PubMed ID: 7757351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of antibody response in meningococcal patients, contacts and vaccinees in north India.
    Rao B; Ayyagari A; Sharma M
    Trop Geogr Med; 1991; 43(1-2):111-3. PubMed ID: 1750098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.